Moayed Ibrahim, MD
Hematology & Oncology · Minot, NDNPI 1124400742
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $882 of the $1,058 with a category attached, or 83.4%. It is spread thinly across 21 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 30 payments — averaging $35.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$235
- E.r. Squibb & Sons, L.L.C.$140
- Pfizer$110
- Daiichi Sankyo Inc.$107
- BTG International Inc.$98
- AVEO Pharmaceuticals, Inc.$75
- plus $294 from 15 others
What the payments were for
- Food & beverage$88283%
- Education$17617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 2 | $235 |
| E.r. Squibb & Sons, L.L.C. | 2 | $140 |
| Pfizer | 2 | $110 |
| Daiichi Sankyo Inc. | 3 | $107 |
| BTG International Inc. | 1 | $98 |
| AVEO Pharmaceuticals, Inc. | 4 | $75 |
| Gilead(2 entities) | 2 | $37 |
| Johnson & Johnson | 1 | $22 |
| Beigene USA, Inc. | 1 | $22 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $20 |
| Array Biopharma Inc | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Amgen | 1 | $19 |
| Tempus AI, Inc | 1 | $19 |
| Bayer | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,058 in reported general payments places this provider in the 60th percentile of 35 hematology & oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 76 | $991,366 |
| CalquenceAcalabrutinib Maleate | 57 | $761,996 |
| PomalystPomalidomide | 31 | $627,797 |
| XtandiEnzalutamide | 42 | $479,203 |
| RevlimidLenalidomide | 25 | $381,474 |
| BrukinsaZanubrutinib | 22 | $331,434 |
| TagrissoOsimertinib Mesylate | 15 | $261,395 |
| ImbruvicaIbrutinib | 13 | $213,161 |
| JakafiRuxolitinib Phosphate | 11 | $156,677 |
| EliquisApixaban | 216 | $150,632 |
| Abiraterone Acetate | 71 | $74,031 |
| Enoxaparin Sodium | 19 | $17,710 |
| XareltoRivaroxaban | 21 | $11,535 |
| Anastrozole | 235 | $5,408 |
| SpsSodium Polystyrene Sulfon/Sorb | 11 | $4,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $14 | $1,023,39272 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $140 | $627,79731 claims |
| Astellas Pharma US IncXtandi | $15 | $479,20342 claims |
| Beigene USA, Inc.Brukinsa | $22 | $331,43422 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $235 | $213,16113 claims |
| PfizerEliquis | $110 | $150,632216 claims |
| Johnson & JohnsonXarelto | $22 | $11,53521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 35 hematology & oncology providers in North Dakota.
Other hematology & oncology in Minot
- Mahendra GuptaFargo$96K
- Radha Krishna VeguntaFargo$37K
- Harish AhujaFargo$26K
- Peter KurnialiBismarck$8K
- Anil PottiGrand Forks$6K
- Matthew McGeeBismarck$3K
- Michael DurandoFargo$2K
- Thandiwe GrayBismarck$2K
- Stewart SharpBismarck$2K
- Sagar RakshitBismarck$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.